Article info

Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases
Free

Authors

  1. Correspondence to Dr Dorry L Segev, Surgery, Johns Hopkins, Baltimore, MD 21218, USA; dorry{at}jhmi.edu
View Full Text

Citation

Chiang TP, Connolly CM, Ruddy JA, et al
Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases

Publication history

  • Received July 11, 2021
  • Accepted August 16, 2021
  • First published August 24, 2021.
Online issue publication 
September 13, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.